Topic: Serum Institute of India
India’s first indigenously developed qHPV against cervical cancer
Recently Serum Institute of India (SII) and Department of Biotechnology (DBT) launched indigenously developed quadrivalent Human Papilloma Virus (HPV) vaccine for prevention of cervical cancer. Highlights The Drug...
IndRa: Cost of vaccinating India’s population above 18 years 0.36% of GDP
The India Ratings and Research (Ind-Ra) recently said the estimated cost to vaccinate all the Indians of age 18 years will be Rs 67,193 crores. This is 0.36%...
PM Takes First Dose of COVID-19 Vaccine
The Prime Minister of India, Narendra Modi, takes first dose of COVID-19 vaccine on March 1, 2021 at AIIMS, New Delhi. After vaccination, he appealed to those people... COVID-19 Vaccination Phase 2 to begin from March 1
The Union Government has announced that the second phase of COVID-19 vaccination will begin from March 1, 2021. Highlights Under the second phase of covid-19 vaccination, people aged...
SII’s Covishield gets emergency-use nod from DGCI
The Subject Expert committee that is advising the Drug Controller General of India (DCGI) recommended restricted Emergency Use Authorisation for COVISHIELD. COVISHIELD vaccine was developed by Serum Institute...
Pneumosil: India’s First Pneumonia Vaccine
The Serum Institute of India recently unveiled the first indigenously developed Pneumococcal Vaccine called Pneumosil. The vaccine was launched by the Union Health Minister Harsh Vardhan. About the... India’s First Indigenous Vaccine against Pneumonia
The first Indian vaccine against Pneumonia has been developed by Serum Institute of India. The vaccine is to be made available to the domestic makers soon. Highlights India...
India-Bangladesh sign MoU on COVID-19 Vaccine
On November 5, 2020, the Government of Bangladesh signed a Memorandum of Understanding with the Serum Institute of India for priority delivery of 3 crore COVID-19 vaccine doses.... COVID-19 Vaccine: Serum Institute of India to produce additional 100 million doses for India
The Serum Institute of India recently announced that it will produce additional 100 million COVID-19 vaccines for low- and middle- income countries by 2021. Highlights Earlier, the institute...
Phase-2 trials of Bharat Biotech vaccine to begin in September
As reported by India Today, the phase I trial for the COVID 19 vaccine made by Bharat Biotech is complete and the Phase II of this trial is...
‘Covishield’ Vaccine to Start Trials in India
The Serum Institute of India is going to launch its first COVID 19 vaccine candidate for trials very soon in India. The vaccine has been named as ‘Covishield’.... 